Ocriplasmin and Vitreoretinal Interface Disorders
In March 2013, Jetrea was approved by the European Union Commission for the treatment of adult VMT, including when associated with a macular hole ≤400 μm. In August 2013, Health Canada—the Federal governing body for Canadian health care—approved intravitreal Jetrea for the treatment of symptomatic VMA. In October 2013, the European Medicines Agency and the National Institute for Health and Care Excellence (NICE) approved the drug for treatment of patients with VMT, including association with a macular hole of diameter ≤400 μm, only if patients have severe symptoms and an epiretinal membrane is not present. The NICE guidance allowed for use of the drug in the National Health Service territory that includes England and Wales. In the same month, the final early benefit assessment from the German Federal Joint Committee officially concluded that Jetrea demonstrates significant added benefit for VMT patients with mild or moderate symptoms. This final guidance confirms the recommendations made previously by the German Institute for Quality and Efficiency in Health Care in August 2013.
International Recommendations on Use of Ocriplasmin
In March 2013, Jetrea was approved by the European Union Commission for the treatment of adult VMT, including when associated with a macular hole ≤400 μm. In August 2013, Health Canada—the Federal governing body for Canadian health care—approved intravitreal Jetrea for the treatment of symptomatic VMA. In October 2013, the European Medicines Agency and the National Institute for Health and Care Excellence (NICE) approved the drug for treatment of patients with VMT, including association with a macular hole of diameter ≤400 μm, only if patients have severe symptoms and an epiretinal membrane is not present. The NICE guidance allowed for use of the drug in the National Health Service territory that includes England and Wales. In the same month, the final early benefit assessment from the German Federal Joint Committee officially concluded that Jetrea demonstrates significant added benefit for VMT patients with mild or moderate symptoms. This final guidance confirms the recommendations made previously by the German Institute for Quality and Efficiency in Health Care in August 2013.